Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

Hepatitis B Clinical Trial

Official title:

A Randomized, Open-Label, Parallel, Multi-Center, Non-inferiority, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Switching to Besifovir Dipivoxil Maleate From Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients Who Pretreated With TDF

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04202536
• Other study ID #: ID-BVCL-403
• Status: Recruiting
• Phase: Phase 4
• Start date: May 29, 2019
• Est. completion date: October 2021

Study information

• Verified date: December 2019
• Source: IlDong Pharmaceutical Co Ltd
• Contact: Yoan Park
• Phone: 82-2-526-3524
• Email: yapark[@]ildong.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A research study to observe the safety, efficacy and tolerability of switching from Tenofovir Disoproxil Fumarate to Besifovir dipivoxil maleate in patients with chronic hepatitis B

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 152
• Est. completion date: October 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. 20 years of age and older, Male or female patients

2. Patients who show positive HBsAg or has a history of chronic hepatitis B for the last six months or more before screening

3. Patients who have been on tenofovir disoproxil fumarate (TDF) monotherapy for more than 48 weeks and are taking TDF at the time of clinical screening

4. At screening, had HBV DNA < 20 IU/mL

5. Patients who were explained about the purpose, methods and effects of the clinical trial and then, signed a written consent form

Exclusion Criteria:

1. Patients who have received interferon (including Pegylation formulation) to treat chronic hepatitis for more than 12 months.

2. Patients who have taken Besifovir

3. Patients who have experienced hepatitis B virus resistance to antiviral drugs

4. Patient diagnosed with a malignant tumor within 5 years before screening or relapsed patient

5. Patient has history of organ transplantation

6. Patients who had received the following drugs for the last two months before screening (however, short-term use (less than consecutive 14 days) of these drugs and low-dose aspirin (100 mg, maximally, 300 mg/day) are allowed.)

• Nephrotoxic drugs (e.g. Aminoglycosides, Amphotericin B, NSAIDs)

• Hepatotoxic drugs (e.g. Erythromycin, Ketoconazole, Rifampin, Fluconazole, Dapsone)

• Anticoagulant (e.g. Warfarin)

7. Patients who are suspected by an investigator to have the level of immunity decreased among patients who had been administered with immunosuppressants within 12 months before screening

8. Patients who had been administered with long-term general corticosteroids (more than consecutive 14 days) at a high dose (more than prednisolone 20 mg daily*) within three months before screening (In case of local corticosteroids, an investigator decides it.)

• It is equal to cortisone 125 mg, hydrocortisone 100 mg, prednisone 20 mg, methylprednisolone 16 mg, triamcinolone 16 mg, dexamethasone 3 mg, betamethasone 2.4 mg

9. Patients who have a past medical history of clinical alcohol or drug abuse within a year before screening or now are abusers

10. Patients with hepatitis C virus, hepatitis D virus or human immunodeficiency virus

11. Patients who have other hepatic diseases (hematochromatosis, Wilson's disease, alcoholic liver diseases, nonalcoholic steatohepatitis, a1-antitrypsin deficiency) except hepatitis B

12. Patient concerned about the decline in daily activity or not able to understand the objectives and methods due to the psychiatric problems

13. Patients who showed Glomerular Filtration Rate (GFR) less than 50 mL/min by calculating Modification of Diet in Renal Disease (MDRD: 1.86 x phosphocreatine -1.154 x age -0.203 (x 0.742 for women)) during screening

14. Patients who showed alpha-fetoprotein(AFP) more than 50 ng/mL during screening and are estimated to have hepatocellular carcinoma (HCC) through liver/abdomen CT scans

15. At least one of the following laboratory values during screening

• Hemoglobin < 9.0 g/dL

• Absolute neutrophil count (ANC) < 1.0 x 10^9 /L (1000 /mm^3)

• Platelet count < 75 x 10^9 /L (100 x 10^3 /mm3)

• Serum creatinine > 1.5 mg/dL

• Serum amylase > 2 x upper limit normal (ULN) and Lipase > 2 x ULN

• Total Bilirubin > 2 x ULN

• Serum albumin < 28 g/L (2.8 g/dL)

16. Pregnant women, lactating women, or patients who planned pregnancy during a trial period

17. Patients who participate in other clinical trials or is supposed to do so during the study period

18. Patients who have hypersensitivity to the clinical trial drug in this clinical trial

19. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

20. Patients who are considered to be unacceptable in this study under the opinion of the investigator

Related Conditions & MeSH terms

• Besifovir Dipivoxil Maleate
• Hepatitis
• Hepatitis B
• Tenofovir Disoproxil Fumarate

Intervention

Drug:
• Besifovir Dipivoxil Maleate
Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
• Tenofovir disoproxil fumarate(TDF)
300 mg tablet administered orally once daily Other Name: VIREAD®

Locations

Country	Name	City	State
Korea, Republic of	Korea University Medical Center	Ansan	Kyounggi-do

Sponsors (1)

Lead Sponsor	Collaborator
IlDong Pharmaceutical Co Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The rate of subjects who maintained hepatitis B virus (HBV) DNA less than 20 IU/mL at the 48th week		at the 48th week
Secondary	The rate of subjects who maintained HBV DNA less than 20 IU/mL at the 24th week		at the 24th week